To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
GenSpera Receives Patent on Second Anti-Cancer Drug, G-115
Read time: Less than a minute
GenSpera, Inc. has announced that its patent application, entitled “Tumor Activated Prodrugs,” has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,635,682. The patent covers the composition and potential uses of G-115, GenSpera’s second anti-cancer drug in development.
“We are also pleased that the term of this patent will extend into the year 2026, which is a very important feature when we enter discussions with future development partners.”
“The issuance of this patent further strengthens our intellectual property position for G-115 and its use in prostate cancer and other prostate pathologies including enlarged prostate,” commented Dr. Craig Dionne, Ph.D., GenSpera CEO and President. “We are also pleased that the term of this patent will extend into the year 2026, which is a very important feature when we enter discussions with future development partners.”
G-115 is a pro-drug that is selectively activated within prostate tumors by an enzyme, Prostate Specific Antigen (PSA), which is active only within prostate tissue and prostate cancer tumors.
In preclinical testing, G-115 was shown to inhibit the growth of tumors in animal models of human prostate cancer. GenSpera, Inc. owns and controls all rights to G-115 and anticipates a strategic partnership to maximize the value of the drug as it progresses through future clinical trials.
“We are also pleased that the term of this patent will extend into the year 2026, which is a very important feature when we enter discussions with future development partners.”
“The issuance of this patent further strengthens our intellectual property position for G-115 and its use in prostate cancer and other prostate pathologies including enlarged prostate,” commented Dr. Craig Dionne, Ph.D., GenSpera CEO and President. “We are also pleased that the term of this patent will extend into the year 2026, which is a very important feature when we enter discussions with future development partners.”
G-115 is a pro-drug that is selectively activated within prostate tumors by an enzyme, Prostate Specific Antigen (PSA), which is active only within prostate tissue and prostate cancer tumors.
In preclinical testing, G-115 was shown to inhibit the growth of tumors in animal models of human prostate cancer. GenSpera, Inc. owns and controls all rights to G-115 and anticipates a strategic partnership to maximize the value of the drug as it progresses through future clinical trials.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
